請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/82132完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 吳泓彥(Hon Yen Wu) | |
| dc.contributor.author | Tse-Yo Alice Huang | en |
| dc.contributor.author | 黃子祐 | zh_TW |
| dc.date.accessioned | 2022-11-25T05:36:33Z | - |
| dc.date.available | 2024-10-12 | |
| dc.date.copyright | 2021-11-09 | |
| dc.date.issued | 2021 | |
| dc.date.submitted | 2021-10-18 | |
| dc.identifier.citation | Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Kurata, T., Chiappori, A., Lee, K. H., de Wit, M., Cho, B. C., Bourhaba, M., Quantin, X., Tokito, T., Mekhail, T., Planchard, D., Kim, Y. C., Karapetis, C. S., Hiret, S., Ostoros, G., PACIFIC Investigators (2018). Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. The New England journal of medicine, 379(24), 2342–2350. https://doi.org/10.1056/NEJMoa1809697 Ashktorab, H., Kupfer, S. S., Brim, H., Carethers, J. M. (2017). Racial disparity in gastrointestinal cancer risk. Gastroenterology, 153(4), 910–923. https://doi.org/10.1053/j.gastro.2017.08.018 Bang, Y. J., Cho, J. Y., Kim, Y. H., Kim, J. W., Di Bartolomeo, M., Ajani, J. A., Yamaguchi, K., Balogh, A., Sanchez, T., Moehler, M. (2017). Efficacy of sequential ipilimumab monotherapy versus best supportive care for unresectable locally advanced/metastatic gastric or gastroesophageal junction cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 23(19), 5671–5678. https://doi.org/10.1158/1078-0432.CCR-17-0025 Bang, Y. J., Ruiz, E. Y., Van Cutsem, E., Lee, K. W., Wyrwicz, L., Schenker, M., Alsina, M., Ryu, M. H., Chung, H. C., Evesque, L., Al-Batran, S. E., Park, S. H., Lichinitser, M., Boku, N., Moehler, M. H., Hong, J., Xiong, H., Hallwachs, R., Conti, I., Taieb, J. (2018). Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300. Annals of oncology : official journal of the European Society for Medical Oncology, 29(10), 2052–2060. https://doi.org/10.1093/annonc/mdy264 Barlesi, F., Vansteenkiste, J., Spigel, D., Ishii, H., Garassino, M., de Marinis, F., Özgüroğlu, M., Szczesna, A., Polychronis, A., Uslu, R., Krzakowski, M., Lee, J. S., Calabrò, L., Arén Frontera, O., Ellers-Lenz, B., Bajars, M., Ruisi, M., Park, K. (2018). Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study. The Lancet. Oncology, 19(11), 1468–1479. https://doi.org/10.1016/S1470-2045(18)30673-9 Barta, J. A., Powell, C. A., Wisnivesky, J. P. (2019). Global Epidemiology of Lung Cancer. Annals of Global Health, 85(1). https://doi.org/10.5334/aogh.2419 Beasley, R. P., Lin, C.-C., Hwang, L.-Y., Chien, C.-S. (1981). Hepatocellular carcinoma and hepatitis B virus. The Lancet, 318(8256), 1129–1133. https://doi.org/10.1016/s0140-6736(81)90585-7 Beer, T. M., Kwon, E. D., Drake, C. G., Fizazi, K., Logothetis, C., Gravis, G., Ganju, V., Polikoff, J., Saad, F., Humanski, P., Piulats, J. M., Gonzalez Mella, P., Ng, S. S., Jaeger, D., Parnis, F. X., Franke, F. A., Puente, J., Carvajal, R., Sengeløv, L., McHenry, M. B., Gerritsen, W. (2017). Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 35(1), 40–47. https://doi.org/10.1200/JCO.2016.69.1584 Bhandari, S., Kumar, R., Nice, L., Cheema, A., Kloecker, G. H. (2020). Racial differences in development of immune-related adverse events. Journal of Clinical Oncology, 38(15_suppl). https://doi.org/10.1200/jco.2020.38.15_suppl.e15148 Blot, W. J., Tarone, R. E. (2015). Doll and Peto's quantitative estimates of cancer risks: Holding generally true for 35 years. JNCI Journal of the National Cancer Institute, 107(4). https://doi.org/10.1093/jnci/djv044 Bonham, V. L., Green, E. D., Pérez-Stable, E. J. (2018). Examining How Race, Ethnicity, and Ancestry Data Are Used in Biomedical Research. JAMA, 320(15), 1533–1534. https://doi.org/10.1001/jama.2018.13609 Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., Barlesi, F., Kohlhäufl, M., Arrieta, O., Burgio, M. A., Fayette, J., Lena, H., Poddubskaya, E., Gerber, D. E., Gettinger, S. N., Rudin, C. M., Brahmer, J. R. (2015). Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. The New England journal of medicine, 373(17), 1627–1639. https://doi.org/10.1056/NEJMoa1507643 Bowcock, A. M., Kidd, J. R., Mountain, J. L., Hebert, J. M., Carotenuto, L., Kidd, K. K., Cavalli-Sforza, L. L. (1991). Drift, admixture, and selection in human evolution: a study with DNA polymorphisms. Proceedings of the National Academy of Sciences of the United States of America, 88(3), 839–843. https://doi.org/10.1073/pnas.88.3.839 Bowcock, A. M., Ruiz-Linares, A., Tomfohrde, J., Minch, E., Kidd, J. R., Cavalli-Sforza, L. L. (1994). High resolution of human evolutionary trees with polymorphic microsatellites. Nature, 368(6470), 455–457. https://doi.org/10.1038/368455a0 Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., Waterhouse, D., Ready, N., Gainor, J., Arén Frontera, O., Havel, L., Steins, M., Garassino, M. C., Aerts, J. G., Domine, M., Paz-Ares, L., Spigel, D. R. (2015). Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. The New England journal of medicine, 373(2), 123–135. https://doi.org/10.1056/NEJMoa1504627 Brody, R., Zhang, Y., Ballas, M., Siddiqui, M. K., Gupta, P., Barker, C., Midha, A., Walker, J. (2017). PD-L1 expression in Advanced Nsclc: Insights into risk stratification and treatment selection from a systematic literature review. Lung Cancer, 112, 200–215. https://doi.org/10.1016/j.lungcan.2017.08.005 Brok, J., Thorlund, K., Gluud, C., Wetterslev, J. (2008). Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. Journal of Clinical Epidemiology, 61(8), 763–769. https://doi.org/10.1016/j.jclinepi.2007.10.007 Burchard, E. G., Ziv, E., Coyle, N., Gomez, S. L., Tang, H., Karter, A. J., Mountain, J. L., Pérez-Stable, E. J., Sheppard, D., Risch, N. (2003). The importance of race and ethnic background in biomedical research and clinical practice. New England Journal of Medicine, 348(12), 1170–1175. https://doi.org/10.1056/nejmsb025007 Bureau, U. S. C. (2020, October 16). About race. The United States Census Bureau. Retrieved September 26, 2021, from https://www.census.gov/topics/population/race/about.html. Calafell, F., Shuster, A., Speed, W. C., Kidd, J. R., Kidd, K. K. (1998). Short tandem repeat polymorphism evolution in humans. European Journal of Human Genetics, 6(1), 38–49. https://doi.org/10.1038/sj.ejhg.5200151 Cancer disparities. National Cancer Institute. (2020, November 17). Retrieved September 27, 2021, from https://www.cancer.gov/about-cancer/understanding/disparities. Center for Drug Evaluation and Research. (2016, October 25). Pembrolizumab (KEYTRUDA) checkpoint inhibitor. U.S. Food and Drug Administration. Retrieved September 28, 2021, from https://www.fda.gov/drugs/resources-information-approved-drugs/pembrolizumab-keytruda-checkpoint-inhibitor. Center for Drug Evaluation and Research. (2020, May 18). FDA approves atezolizumab For first-line treatment of metastatic NSCLC. U.S. Food and Drug Administration. Retrieved September 28, 2021, from https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-first-line-treatment-metastatic-nsclc-high-pd-l1-expression. Chen, L.T., Kang, Y.-K., Satoh, T., Chao, Y., Kato, K., Chung, H. C., Chen, J.S., Muro, K., Kang, W. K., Yoshikawa, T., Oh, S. C., Tamura, T., Lee, K. W., Boku, N. (2020). A phase III study of nivolumab (Nivo) in previously treated Advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Three-year update data. Journal of Clinical Oncology, 38(4_suppl), 383–383. https://doi.org/10.1200/jco.2020.38.4_suppl.383 Choueiri, T. K., Motzer, R. J., Rini, B. I., Haanen, J., Campbell, M. T., Venugopal, B., Kollmannsberger, C., Gravis-Mescam, G., Uemura, M., Lee, J. L., Grimm, M. O., Gurney, H., Schmidinger, M., Larkin, J., Atkins, M. B., Pal, S. K., Wang, J., Mariani, M., Krishnaswami, S., Cislo, P., Albiges, L. (2020). Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Annals of oncology : official journal of the European Society for Medical Oncology, 31(8), 1030–1039. https://doi.org/10.1016/j.annonc.2020.04.010 Cohen, E., Soulières, D., Le Tourneau, C., Dinis, J., Licitra, L., Ahn, M. J., Soria, A., Machiels, J. P., Mach, N., Mehra, R., Burtness, B., Zhang, P., Cheng, J., Swaby, R. F., Harrington, K. J., KEYNOTE-040 investigators (2019). Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. The Lancet, 393(10167), 156–167. https://doi.org/10.1016/S0140-6736(18)31999-8 Conforti, F., Pala, L., Bagnardi, V., De Pas, T., Martinetti, M., Viale, G., Gelber, R. D., Goldhirsch, A. (2018). Cancer immunotherapy efficacy and patients' sex: A systematic review and meta-analysis. The Lancet Oncology, 19(6), 737–746. https://doi.org/10.1016/s1470-2045(18)30261-4 Conforti, F., Pala, L., Bagnardi, V., Viale, G., De Pas, T., Pagan, E., Pennacchioli, E., Cocorocchio, E., Ferrucci, P. F., De Marinis, F., Gelber, R. D., Goldhirsch, A. (2019). Sex-based heterogeneity in response to lung cancer immunotherapy: A systematic review and meta-analysis. Journal of the National Cancer Institute, 111(8), 772–781. https://doi.org/10.1093/jnci/djz094 Das, T., Andrieux, G., Ahmed, M., Chakraborty, S. (2020). Integration of Online Omics-Data Resources for Cancer Research. Frontiers in genetics, 11, 578345. https://doi.org/10.3389/fgene.2020.578345 Davies, M., Duffield, E. A. (2017). Safety of checkpoint inhibitors for cancer treatment: Strategies for patient monitoring and management of immune-mediated adverse events. ImmunoTargets and Therapy, Volume 6, 51–71. https://doi.org/10.2147/itt.s141577 Davis, A. A., Patel, V. G. (2019). The role of PD-L1 expression as a predictive biomarker: An analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. Journal for Immunotherapy of Cancer, 7(1), 278. https://doi.org/10.1186/s40425-019-0768-9 Divisi, D., Di Tommaso, S., Salvemini, S., Garramone, M., Crisci, R. (2006). Diet and cancer. Acta bio-medica : Atenei Parmensis, 77(2), 118–123. Egede, L. E. (2006). Race, ethnicity, culture, and disparities in health care. Journal of General Internal Medicine, 21(6), 667–669. https://doi.org/10.1111/j.1525-1497.2006.0512.x Elias, R., Morales, J., Rehman, Y., Khurshid, H. (2016). Immune checkpoint inhibitors in older adults. Current Oncology Reports, 18(8), 47. https://doi.org/10.1007/s11912-016-0534-9 El–Serag, H. B., Rudolph, K. L. (2007). Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology, 132(7), 2557–2576. https://doi.org/10.1053/j.gastro.2007.04.061 Emambux, S., Tachon, G., Junca, A., Tougeron, D. (2018). Results and challenges of immune checkpoint inhibitors in colorectal cancer. Expert Opinion on Biological Therapy, 18(5), 561–573. https://doi.org/10.1080/14712598.2018.1445222 Eng, C., Kim, T. W., Bendell, J., Argilés, G., Tebbutt, N. C., Di Bartolomeo, M., Falcone, A., Fakih, M., Kozloff, M., Segal, N. H., Sobrero, A., Yan, Y., Chang, I., Uyei, A., Roberts, L., Ciardiello, F., IMblaze370 Investigators (2019). Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. The Lancet. Oncology, 20(6), 849–861. https://doi.org/10.1016/S1470-2045(19)30027-0 Fagerberg, B. (1999). Effect of metoprolol CR/Xl in chronic heart failure: Metoprolol CR/XL randomised intervention Trial in congestive heart failure (MERIT-HF). The Lancet, 353(9169), 2001–2007. https://doi.org/10.1016/s0140-6736(99)04440-2 Fasani, P., Sangiovanni, A., De Fazio, C., Borzio, M., Bruno, S., Ronchi, G., Del Ninno, E., Colombo, M. (1999). High prevalence of multinodular hepatocellular carcinoma in patients with cirrhosis attributable to multiple risk factors. Hepatology, 29(6), 1704–1707. https://doi.org/10.1002/hep.510290604 Fashoyin-Aje, L. A., Fernandes, L. L., Lemery, S., Keegan, P., Sridhara, R., Bull, J. C., Pazdur, R. (2017). Asian representation in clinical trials of new drugs for the treatment of cancer. Journal of Clinical Oncology, 35(15_suppl), 6564–6564. https://doi.org/10.1200/jco.2017.35.15_suppl.6564 Ferdinand, K. C., Igari, M. (2018). The role of racial/ethnic factors in global clinical trials. Expert Review of Clinical Pharmacology, 11(9), 829–832. https://doi.org/10.1080/17512433.2018.1510311 Ferris, R. L., Blumenschein, G. R., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L. F., Harrington, K. J., Kasper, S., Vokes, E. E., Even, C., Worden, F. P., Haddad, R. I., Kiyota, N., Tahara, M., Monga, M., Lynch, M. J., Geese, W. J., Kopit, J., Shaw, J. W., Gillison, M. L. (2016). Further evaluations of Nivolumab (nivo) versus investigator’s choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141. Journal of Clinical Oncology, 34(15_suppl), 6009–6009. https://doi.org/10.1200/jco.2016.34.15_suppl.6009 Finn, R. S., Ryoo, B. Y., Merle, P., Kudo, M., Bouattour, M., Lim, H. Y., Breder, V., Edeline, J., Chao, Y., Ogasawara, S., Yau, T., Garrido, M., Chan, S. L., Knox, J., Daniele, B., Ebbinghaus, S. W., Chen, E., Siegel, A. B., Zhu, A. X., Cheng, A. L., KEYNOTE-240 investigators (2020). Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: A randomized, double-blind, phase III trial. Journal of Clinical Oncology : official journal of the American Society of Clinical Oncology, 38(3), 193–202. https://doi.org/10.1200/JCO.19.01307 Fisher, D. J., Carpenter, J. R., Morris, T. P., Freeman, S. C., Tierney, J. F. (2017). Meta-analytical methods to identify who benefits most from treatments: Daft, deluded, or deft approach? BMJ. https://doi.org/10.1136/bmj.j573 Food and Drug Administration (FDA), U.S. Department of Health and Human Services (HHS), Office of the Commissioner (OC), Office of Minority Health (OMH), Office of Women’s Health (OWH), Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Center for Devices and Radiologic Health (CDRH). (2016, October 26). Collection of race and ethnicity data in clinical trials. U.S. Food and Drug Administration. Retrieved September 27, 2021, from https://www.fda.gov/regulatory-information/search-fda-guidance-documents/collection-race-and-ethnicity-data-clinical-trials. Freedman, N. D., Abnet, C. C., Caporaso, N. E., Fraumeni, J. F., Jr, Murphy, G., Hartge, P., Hollenbeck, A. R., Park, Y., Shiels, M. S., Silverman, D. T. (2016). Impact of changing US cigarette smoking patterns on incident cancer: risks of 20 smoking-related cancers among the women and men of the NIH-AARP cohort. International journal of epidemiology, 45(3), 846–856. https://doi.org/10.1093/ije/dyv175 Friedlaender, A., Kim, C., Addeo, A. (2020). Rethinking the optimal duration of immune checkpoint inhibitors in non-small cell lung cancer throughout the covid-19 pandemic. Frontiers in Oncology, 10, 862. https://doi.org/10.3389/fonc.2020.00862 Galsky, M. D., Arija, J., Bamias, A., Davis, I. D., De Santis, M., Kikuchi, E., Garcia-Del-Muro, X., De Giorgi, U., Mencinger, M., Izumi, K., Panni, S., Gumus, M., Özgüroğlu, M., Kalebasty, A. R., Park, S. H., Alekseev, B., Schutz, F. A., Li, J. R., Ye, D., Vogelzang, N. J., IMvigor130 Study Group (2020). Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. The Lancet, 395(10236), 1547–1557. https://doi.org/10.1016/S0140-6736(20)30230-0 Goss, P. E., Strasser-Weippl, K., Lee-Bychkovsky, B. L., Fan, L., Li, J., Chavarri-Guerra, Y., Liedke, P. E., Pramesh, C. S., Badovinac-Crnjevic, T., Sheikine, Y., Chen, Z., Qiao, Y. L., Shao, Z., Wu, Y. L., Fan, D., Chow, L. W., Wang, J., Zhang, Q., Yu, S., Shen, G., Chan, A. (2014). Challenges to effective cancer control in China, India, and Russia. The Lancet. Oncology, 15(5), 489–538. https://doi.org/10.1016/S1470-2045(14)70029-4 Govindan, R., Szczesna, A., Ahn, M. J., Schneider, C. P., Gonzalez Mella, P. F., Barlesi, F., Han, B., Ganea, D. E., Von Pawel, J., Vladimirov, V., Fadeeva, N., Lee, K. H., Kurata, T., Zhang, L., Tamura, T., Postmus, P. E., Jassem, J., O'Byrne, K., Kopit, J., Li, M., Reck, M. (2017). Phase III trial of ipilimumab combined with paclitaxel and carboplatin in advanced squamous non-small-cell lung cancer. Journal of Clinical Oncology : official journal of the American Society of Clinical Oncology, 35(30), 3449–3457. https://doi.org/10.1200/JCO.2016.71.7629 Grassadonia, A., Sperduti, I., Vici, P., Iezzi, L., Brocco, D., Gamucci, T., Pizzuti, L., Maugeri-Saccà, M., Marchetti, P., Cognetti, G., De Tursi, M., Natoli, C., Barba, M., Tinari, N. (2018). Effect of gender on the outcome of patients receiving immune checkpoint inhibitors for advanced cancer: A systematic review and meta-analysis of phase III randomized clinical trials. Journal of Clinical Medicine, 7(12), 542. https://doi.org/10.3390/jcm7120542 Grenade, C., Phelps, M. A., Villalona-Calero, M. A. (2014). Race and ethnicity in cancer therapy: What have we learned? Clinical Pharmacology Therapeutics, 95(4), 403–412. https://doi.org/10.1038/clpt.2014.5 Gyawali, B., Shimokata, T., Ando, Y. (2017). Correlation and differences in effect sizes between progression free survival (PFS) and overall survival (OS) among PD-1 inhibitors. Annals of Oncology, 28, v411. https://doi.org/10.1093/annonc/mdx376.022 Haque, W., Verma, V., Butler, E. B., Teh, B. S. (2019). Racial and socioeconomic disparities in the delivery of immunotherapy for metastatic melanoma in the United States. Journal of immunotherapy (Hagerstown, Md. : 1997), 42(6), 228–235. https://doi.org/10.1097/CJI.0000000000000264 Haslam, A., Prasad, V. (2019). Estimation of the percentage of us patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Network Open, 2(5). https://doi.org/10.1001/jamanetworkopen.2019.2535 Hegde, P. S., Chen, D. S. (2020). Top 10 challenges in cancer immunotherapy. Immunity, 52(1), 17–35. https://doi.org/10.1016/j.immuni.2019.12.011 Heiat, A., Gross, C. P., Krumholz, H. M. (2002). Representation of the elderly, women, and minorities in heart failure clinical trials. Archives of Internal Medicine, 162(15), 1682-1688. https://doi.org/10.1001/archinte.162.15.1682 Herbst, R. S., Baas, P., Kim, D.W., Felip, E., Pérez-Gracia, J. L., Han, J.Y., Molina, J., Kim, J.H., Arvis, C. D., Ahn, M.J., Majem, M., Fidler, M. J., de Castro, G., Garrido, M., Lubiniecki, G. M., Shentu, Y., Im, E., Dolled-Filhart, M., Garon, E. B. (2016). Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. The Lancet, 387(10027), 1540–1550. https://doi.org/10.1016/s0140-6736(15)01281-7 Herbst, R. S., Giaccone, G., de Marinis, F., Reinmuth, N., Vergnenegre, A., Barrios, C. H., Morise, M., Felip, E., Andric, Z., Geater, S., Özgüroğlu, M., Zou, W., Sandler, A., Enquist, I., Komatsubara, K., Deng, Y., Kuriki, H., Wen, X., McCleland, M., Mocci, S., Spigel, D. R. (2020). Atezolizumab for first-line treatment of PD-L1–Selected patients with NSCLC. The New England Journal of Medicine, 383(14), 1328–1339. https://doi.org/10.1056/nejmoa1917346 Hernandez, A. V., Marti, K. M., Roman, Y. M. (2020). Meta-Analysis. Chest, 158(1), S97-S102. https://doi.org/10.1016/j.chest.2020.03.003 Hida, T., Kaji, R., Satouchi, M., Ikeda, N., Horiike, A., Nokihara, H., Seto, T., Kawakami, T., Nakagawa, S., Kubo, T. (2018). Atezolizumab in Japanese patients with previously treated advanced non–small-cell lung Cancer: A subgroup analysis of the Phase 3 OAK Study. Clinical Lung Cancer, 19(4). https://doi.org/10.1016/j.cllc.2018.01.004 Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., Akerley, W., van den Eertwegh, A. J., Lutzky, J., Lorigan, P., Vaubel, J. M., Linette, G. P., Hogg, D., Ottensmeier, C. H., Lebbé, C., Peschel, C., Urba, W. J. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. The New England journal of medicine, 363(8), 711–723. https://doi.org/10.1056/NEJMoa1003466 Hsu, W. H., Yang, J. C., Mok, T. S., Loong, H. H. (2018). Overview of current systemic management Of EGFR-mutant NSCLC. Annals of Oncology: official journal of the European Society for Medical Oncology, 29(suppl_1_, i3–i9. https://doi.org/10.1093/annonc/mdx702 Ibaraki, A. Y., Hall, G. C., Sabin, J. A. (2014). Asian American cancer disparities: The potential effects of model minority health stereotypes. Asian American Journal of Psychology, 5(1), 75–81. https://doi.org/10.1037/a0036114 Idossa, D., Duma, N., Chekhovskiy, K., Go, R., Ailawadhi, S. (2018). Commentary: Race and ethnicity in biomedical research – classifications, challenges, and future directions. Ethnicity Disease, 28(4), 561–564. https://doi.org/10.18865/ed.28.4.561 Islami, F., Torre, L. A., Jemal, A. (2015). Global trends of lung cancer mortality and smoking prevalence. Translational lung cancer research, 4(4), 327–338. https://doi.org/10.3978/j.issn.2218-6751.2015.08.04 Jotte, R., Cappuzzo, F., Vynnychenko, I., Stroyakovskiy, D., Rodríguez-Abreu, D., Hussein, M., Soo, R., Conter, H. J., Kozuki, T., Huang, K. C., Graupner, V., Sun, S. W., Hoang, T., Jessop, H., McCleland, M., Ballinger, M., Sandler, A., Socinski, M. A. (2020). Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131): Results from a randomized phase III trial. Journal of Thoracic Oncology: official publication of the International Association for the Study of Lung Cancer, 15(8), 1351–1360. https://doi.org/10.1016/j.jtho.2020.03.028 Kato, K., Cho, B. C., Takahashi, M., Okada, M., Lin, C. Y., Chin, K., Kadowaki, S., Ahn, M. J., Hamamoto, Y., Doki, Y., Yen, C. C., Kubota, Y., Kim, S. B., Hsu, C. H., Holtved, E., Xynos, I., Kodani, M., Kitagawa, Y. (2019). Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): A multicentre, randomised, open-label, phase 3 trial. The Lancet Oncology, 20(11), 1506–1517. https://doi.org/10.1016/s1470-2045(19)30626-6 Kaur, A., Webster, M. R., Marchbank, K., Behera, R., Ndoye, A., Kugel, C. H., 3rd, Dang, V. M., Appleton, J., O'Connell, M. P., Cheng, P., Valiga, A. A., Morissette, R., McDonnell, N. B., Ferrucci, L., Kossenkov, A. V., Meeth, K., Tang, H. Y., Yin, X., Wood, W. H., 3rd, Lehrmann, E., Weeraratna, A. T. (2016). sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature, 532(7598), 250–254. https://doi.org/10.1038/nature17392 Kim, J., Mailey, B., Senthil, M., Artinyan, A., Sun, C.-L., Bhatia, S. (2009). Disparities in gastric cancer outcomes among Asian ethnicities in the USA. Annals of Surgical Oncology, 16(9), 2433–2441. https://doi.org/10.1245/s10434-009-0584-4 Kimura, T., Egawa, S. (2018). Epidemiology of prostate cancer in Asian countries. International Journal of Urology : official journal of the Japanese Urological Association, 25(6), 524–531. https://doi.org/10.1111/iju.13593 Klein, S. L., Flanagan, K. L. (2016). Sex differences in immune responses. Nature Reviews. Immunology, 16(10), 626–638. https://doi.org/10.1038/nri.2016.90 Kugel, C. H., Douglass, S. M., Webster, M. R., Kaur, A., Liu, Q., Yin, X., Weiss, S. A., Darvishian, F., Al-Rohil, R. N., Ndoye, A., Behera, R., Alicea, G. M., Ecker, B. L., Fane, M., Allegrezza, M. J., Svoronos, N., Kumar, V., Wang, D. Y., Somasundaram, R., Weeraratna, A. T. (2018). Age correlates with response to anti-pd1, reflecting age-related differences in intratumoral effector and regulatory T-Cell Populations. Clinical Cancer Research: an official journal of the American Association for Cancer Research, 24(21), 5347–5356. https://doi.org/10.1158/1078-0432.ccr-18-1116 Kuhl, E. (2019, June 5). Opportunities and challenges in immunotherapy for gastric and esophageal cancers. ASCO Daily News. Retrieved September 28, 2021, from https://dailynews.ascopubs.org/do/10.1200/ADN.19.190338/full/. Kuo, C. N., Liao, Y. M., Kuo, L. N., Tsai, H. J., Chang, W. C., Yen, Y. (2020). Cancers in Taiwan: Practical insight from epidemiology, treatments, biomarkers, and cost. Journal of the Formosan Medical Association, 119(12), 1731–1741. https://doi.org/10.1016/j.jfma.2019.08.023 Lam, W. K., White, N. W., Chan-Yeung, M. M. (2004). Lung cancer epidemiology and risk factors in Asia and Africa. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 8(9), 1045–1057. Lee, R. J., Madan, R. A., Kim, J., Posadas, E. M., Yu, E. Y. (2021). Disparities in cancer care and the Asian American population. The Oncologist, 26(6), 453–460. https://doi.org/10.1002/onco.13748 Li, J., Gu, J. (2019). Efficacy of immune checkpoint inhibitors in cancer patients of different ages: A meta-analysis. Future Oncology, 15(31), 3633–3646. https://doi.org/10.2217/fon-2019-0279 Liang, F., Zhang, S., Wang, Q., Li, W. (2018). Treatment effects measured by restricted mean survival time in trials of immune checkpoint inhibitors for cancer. Annals of Oncology, 29(5), 1320–1324. https://doi.org/10.1093/annonc/mdy075 Liao, H., Chen, W., Dai, Y., Richardson, J. J., Guo, J., Yuan, K., Zeng, Y., Xie, K. (2019). Expression of programmed cell death-ligands in hepatocellular carcinoma: Correlation with immune microenvironment and survival outcomes. Frontiers in Oncology, 9, 883. https://doi.org/10.3389/fonc.2019.00883 Lin, P. Y., Sun, L., Thibodeaux, S. R., Ludwig, S. M., Vadlamudi, R. K., Hurez, V. J., Bahar, R., Kious, M. J., Livi, C. B., Wall, S. R., Chen, L., Zhang, B., Shin, T., Curiel, T. J. (2010). B7-h1–dependent sex-related differences in tumor immunity and immunotherapy responses. Journal of Immunology, 185(5), 2747–2753. https://doi.org/10.4049/jimmunol.1000496 Lin, S., Liu, X., Yao, B., Huang, Z. (2018). Controlling for confounding factors and revealing their interactions in genetic association meta-analyses: a computing method and application for stratification analyses. Oncotarget, 9(15), 12125–12136. https://doi.org/10.18632/oncotarget.24335 Linnenbringer, E., Geronimus, A. T., Davis, K. L., Bound, J., Ellis, L., Gomez, S. L. (2020). Associations between breast cancer subtype and neighborhood socioeconomic and racial composition among Black and White women. Breast Cancer Research and Treatment, 180(2), 437–447. https://doi.org/10.1007/s10549-020-05545-1 Linton, P. J., Dorshkind, K. (2004). Age-related changes in lymphocyte development and function. Nature Immunology, 5(2), 133–139. https://doi.org/10.1038/ni1033 Loree, J. M., Anand, S., Dasari, A., Unger, J. M., Gothwal, A., Ellis, L. M., Varadhachary, G., Kopetz, S., Overman, M. J., Raghav, K. (2019). Disparity of race reporting and representation in clinical Trials leading to cancer drug approvals from 2008 to 2018. JAMA Oncology, 5(10). https://doi.org/10.1001/jamaoncol.2019.1870 McCracken, M., Olsen, M., Chen, M. S., Jemal, A., Thun, M., Cokkinides, V., Deapen, D., Ward, E. (2007). Cancer incidence, mortality, and associated risk factors among Asian Americans of Chinese, Filipino, Vietnamese, Korean, and Japanese ethnicities. CA: A Cancer Journal for Clinicians, 57(4), 190–205. https://doi.org/10.3322/canjclin.57.4.190 Moore, M.A., Yoo, K., Tuncer, M.A., Sobue, T. (2010). Overview of players and information in the cancer epidemiology and control world in Asia. Asian Pacific Journal of Cancer Prevention : APJCP, 11 Suppl 2, 1-10 . Mountain, J. L., Cavalli-Sforza, L. L. (1997). Multilocus genotypes, a tree of individuals, and human evolutionary history. The American Journal of Human Genetics, 61(3), 705–718. https://doi.org/10.1086/515510 Murthy, V. H., Krumholz, H. M., Gross, C. P. (2004). Participation in cancer clinical trials. JAMA, 291(22), 2720. https://doi.org/10.1001/jama.291.22.2720 Mushti, S. L., Mulkey, F., Sridhara, R. (2018). Evaluation of overall response rate and progression-free survival as potential surrogate endpoints for overall survival in immunotherapy trials. Clinical Cancer Research, 24(10), 2268–2275. https://doi.org/10.1158/1078-0432.ccr-17-1902 Nakamura, Y. (2019). Biomarkers for immune checkpoint inhibitor-mediated tumor response and adverse events. Frontiers in Medicine, 6, 119. https://doi.org/10.3389/fmed.2019.00119 Nazha, B., Goyal, S., Chen, Z., Engelhart, A., Carlisle, J. W., Beardslee, T. J., Gill, H., Odikadze, L., Liu, Y., Mishra, M. K., Ramalingam, S. S., Owonikoko, T. K. (2020). Efficacy and safety of immune checkpoint blockade in self‐identified Black patients with advanced non–small cell lung cancer. Cancer, 126(23), 5040–5049. https://doi.org/10.1002/cncr.33141 Nazha, B., Mishra, M., Pentz, R., Owonikoko, T. K. (2019). Enrollment of racial minorities in clinical trials: Old problem assumes new urgency in the age of immunotherapy. American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting, (39), 3–10. https://doi.org/10.1200/edbk_100021 Office of minority health. (2021, August 26). Cancer and Asian Americans. U.S. Department of Health and Human Services - The Office of Minority Health. Retrieved September 28, 2021, from https://minorityhealth.hhs.gov/omh/browse.aspx?lvl=4 lvlid=46. Ortona, E., Pierdominici, M., Rider, V. (2019). Editorial: Sex hormones and gender differences in immune responses. Frontiers in Immunology, 10, 1076. https://doi.org/10.3389/fimmu.2019.01076 Parkin, D. M. (2006). The global health burden of Infection-associated cancers in the year 2002. International Journal of Cancer, 118(12), 3030–3044. https://doi.org/10.1002/ijc.21731 Paz-Ares, L., Dvorkin, M., Chen, Y., Reinmuth, N., Hotta, K., Trukhin, D., Statsenko, G., Hochmair, M. J., Özgüroğlu, M., Ji, J. H., Voitko, O., Poltoratskiy, A., Ponce, S., Verderame, F., Havel, L., Bondarenko, I., Kazarnowicz, A., Losonczy, G., Conev, N. V., Armstrong, J., CASPIAN investigators (2019). Durvalumab plus platinum-etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung Cancer (CASPIAN): A randomised, controlled, open-label, phase 3 trial. The Lancet, 394(10212), 1929–1939. https://doi.org/10.1016/s0140-6736(19)32222-6 Peng, L., Wu, Y. L. (2018). Immunotherapy in the Asiatic population: Any differences from Caucasian population? Journal of Thoracic Disease, 10(Suppl 13), S1482-1493. https://doi.org/10.21037/jtd.2018.05.106 Peng, L., Qin, B. D., Xiao, K., Xu, S., Yang, J. S., Zang, Y. S., Stebbing, J., Xie, L. P. (2020). A meta-analysis comparing responses of Asian versus non-Asian cancer patients to PD-1 and PD-L1 inhibitor-based therapy. OncoImmunology, 9(1), 1781333. https://doi.org/10.1080/2162402x.2020.1781333 Peravali, M., Gomes-Lima, C., Tefera, E., Baker, M., Sherchan, M., Farid, S., Burman, K., Constantinescu, F., Veytsman, I. (2021). Racial disparities in immune-related adverse events of immune checkpoint inhibitors and association with survival ……… | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/82132 | - |
| dc.description.abstract | "背景 近年來，免疫檢查點抑製劑（Immune checkpoint inhibitors）已成為一類重要的癌症治療方法。根據文獻報告，免疫檢查點抑製劑或其組合治療效果在不同癌症類型存在很大的個體差異，目前觀察到的反應率約莫在15％到25％之間; 而造成該療效差異的預後因子仍在研究中，尚未得出一致的結論。統合分析已被應用於探討多種預後因子，包括PD-1和PD-L1表現，其他數種生物標記如年齡以及性別。本研究旨在針對白種人與亞洲人, 透過統合分析探討種族對免疫檢查點抑制的影響。 方法 作者從Pubmed和Embase數據庫中進行了系統性文獻檢索，搜尋自2015年1月1日至2020年12月30日之間相關的隨機對照試驗。我們萃取了27項研究比較了免疫檢查點抑製劑與標准治療（Standard of Care）或安慰劑 (Placebo) 在亞洲人以及白種人整體存活療效的隨機分派試驗 (Randomized Controlled Trials) 。非隨機分派試驗，生物標記研究，世代研究，回顧性研究，社論，評論文章均不包含在分析內。統合分析是在隨機效應模型下各別採用deft (靈巧的, 意即僅考量研究內的交互作用) 和deluded (誤導的, 意即考量研究間的以及研究內的交互作用)以統合迴歸方法進行，然後進行試驗序列分析(Trials sequential analysis, TSA)，以查看該信息量是否已達到有統計學意義的閾值。 結果 所有27項研究的統合分析顯示，在混合效應模型下，亞洲人（hazard ratio [HR] 0.81; 95％CI 0.72-0.92; p = 0.07）和白種人（HR 0.83; 95％CI 0.76-0.90; p <0.01）使用免疫檢查點抑製劑相對於對照組均有整體存活優勢。使用統合迴歸分析並未觀察到兩個族群的整體存活效益之間存在有統計上顯著差異（p = 0.8407）。按第幾線治療、癌症部位、是否與化療合併使用, 以及免疫檢查點抑制劑種類分層的子分析，在亞洲人和白種人之間在免疫療法的療效上也沒有統計上的顯著差異。同樣的，試驗序列分析的數據顯示在亞洲人和白種人兩組之間沒有統計上差異，且在80％ power的設定下，增加更多試驗可能不會改變結果。 討論及結論 通過這項統合分析，並且結合試驗序列分析數個免疫檢查點抑製劑的隨機臨床試驗結果，無論是亞洲和白種人的分析結果均顯示了相對於標準治療或是安慰劑, 免疫療法治療的整體存活療效較佳; 且兩組相比，無統計上差異。該結果表示在亞裔或白種人種族使用免疫治療時應可預期相近的治療效果。" | zh_TW |
| dc.description.provenance | Made available in DSpace on 2022-11-25T05:36:33Z (GMT). No. of bitstreams: 1 U0001-1010202111460700.pdf: 6633591 bytes, checksum: e80b99aa3c62debd308d44ab14f60b9a (MD5) Previous issue date: 2021 | en |
| dc.description.tableofcontents | 致謝 ii 中文摘要 1 Synopsis 3 圖 目 錄 7 表 目 錄 8 本文 1 Introduction 9 1.1 Mechanism and current state of ICIs 9 1.2 Major biomarkers under research 12 1.2.1 PD-L1 expression 12 1.2.2 Sex 14 1.2.3 Age 16 1.2.4 Race 18 2 Methods and Materials 37 2.1 Study design 37 2.2 Inclusion exclusion criteria 38 2.3 Statistical Analysis 39 3 Results 42 3.1 Systematic review 42 3.2 Meta-analysis (Meta-regression) 44 3.3 Subgroup Analysis 45 3.4 Trial Sequential Analysis 46 3.5 Progression Free Survival Analysis 46 4 Discussion 62 5 Conclusion 70 Reference……………………………………………………………………………72 圖 目 錄 Figure 1. PRISMA Diagram 47 Figure 2 A) Overall survival for Asian (Studies reported both Asian and White OS). 58 Figure 2 B) Overall survival for White (Studies reported both Asian and White OS).58 Figure 2 C) Clinical outcomes between Asian and White patients with ICI treatment59 Figure 3 A) Overall survival for Asian (All data) 59 Figure 3 B) Overall survival for White (All data)……………………………………60 Figure 4 Trials series analysis based on 14 included studies 61 Figure 5 A) Progression free survival for Asian (All data)………………………..…61 Figure 5 B) Progression free survival for White (All data)…………………………..61 Supplemantary Figure S1. Funnel plot and eggers test for publication bias………………………...112 Figure S2. Summary of overall survival in meta-analysis………………………….116 表 目 錄 Table 1. Characteristics of 27 included randomized controlled trials 48 Table 2. Racial subgroup analysis for ICI treatment efficacy differences 60 Supplementary Table S1. Jadad quality score of included studies……………………...…………….97 Table S2. Cochrane Risk of Bias excel tool………………………………………....99 Table S3. Racial stratification and participating countries of 27 included studies…101 | |
| dc.language.iso | en | |
| dc.subject | 統合分析 | zh_TW |
| dc.subject | 免疫檢查點抑制劑 | zh_TW |
| dc.subject | 種族 | zh_TW |
| dc.subject | 試驗序列分析 | zh_TW |
| dc.subject | PD-1 | zh_TW |
| dc.subject | CTLA-4 | zh_TW |
| dc.subject | PD-L1 | zh_TW |
| dc.subject | Meta-analysis | en |
| dc.subject | CTLA-4 | en |
| dc.subject | PD-L1 | en |
| dc.subject | PD-1 | en |
| dc.subject | Trial Series Analysis | en |
| dc.subject | Race | en |
| dc.subject | Immune checkpoint inhibitors | en |
| dc.title | 免疫檢查點抑制劑之有效性與種族(白種人與亞洲人)之相關性: 系統性回顧與統合分析 | zh_TW |
| dc.title | Efficacy of Immune Checkpoint Inhibitors and Association with Races (Among White and Asian): A Systematic Review and Meta-analysis | en |
| dc.date.schoolyear | 109-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.coadvisor | 杜裕康(Yu Kang Tu) | |
| dc.contributor.oralexamcommittee | 簡國龍(Hsin-Tsai Liu),許駿(Chih-Yang Tseng) | |
| dc.subject.keyword | 統合分析,免疫檢查點抑制劑,種族,試驗序列分析,PD-1,PD-L1,CTLA-4, | zh_TW |
| dc.subject.keyword | Meta-analysis,Immune checkpoint inhibitors,Race,Trial Series Analysis,PD-1,PD-L1,CTLA-4, | en |
| dc.relation.page | 116 | |
| dc.identifier.doi | 10.6342/NTU202103639 | |
| dc.rights.note | 同意授權(限校園內公開) | |
| dc.date.accepted | 2021-10-19 | |
| dc.contributor.author-college | 公共衛生學院 | zh_TW |
| dc.contributor.author-dept | 流行病學與預防醫學研究所 | zh_TW |
| dc.date.embargo-lift | 2024-10-12 | - |
| 顯示於系所單位： | 流行病學與預防醫學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| U0001-1010202111460700.pdf 授權僅限NTU校內IP使用（校園外請利用VPN校外連線服務） | 6.48 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。